Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions


Answer 1
  1. Large B-cell lymphoma (large transformed cell lymphoma). Peripheral T-cell lymphoma and large B-cell lymphoma (large transformed cell lymphoma) are both intermediate grade lymphomas, according to the Working Formulation of Non-Hodgkin’s Lymphomas. For intermediate grade lymphomas, cure rates with initial chemotherapy are 40% to 45%.1 Patients with anaplastic large T-cell lymphoma have a prognosis similar to that of patients with large B-cell lymphoma, whereas patients with peripheral T-cell lymphoma have a cure rate nearer to 20%.2 Mantle cell lymphoma is a small cell lymphoma distinct from diffuse, small cleaved cell lymphoma. Although response rates to initial therapy are excellent, relapses often occur, and cures with any treatment - including stem cell transplantation - are extremely rare. Small cleaved cell lymphoma is a slowly progressive, indolent, incurable lymphoma except in very rare patients with stage I disease, who may be cured by radiation therapy. This patient has stage III disease. Small noncleaved cell lymphoma (Burkitt’s lymphoma) is a high-grade lymphoma with a 20% to 40% chance of cure with aggressive combination chemotherapy. However, survival in the absence of a complete remission is usually quite brief.

     Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1002-6.

    2. Siegert W, Agthe A, Griesser H, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992;117:364-70.

Click here to return to the questions


Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 1/04/08 • kkj